{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Breast neoplasm", "bone loss", "dyslipidemia"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37096936", "DateCompleted": {"Year": "2023", "Month": "04", "Day": "26"}, "DateRevised": {"Year": "2023", "Month": "04", "Day": "28"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.1080/13880209.2023.2203193"], "Journal": {"ISSN": "1744-5116", "JournalIssue": {"Volume": "61", "Issue": "1", "PubDate": {"Year": "2023", "Month": "Dec"}}, "Title": "Pharmaceutical biology", "ISOAbbreviation": "Pharm Biol"}, "ArticleTitle": "Chinese medicinal herbs for reducing endocrine therapy-induced side effects in patients with hormone receptor-positive breast cancer: a systematic review and meta-analysis.", "Pagination": {"StartPage": "722", "EndPage": "736", "MedlinePgn": "722-736"}, "Abstract": {"AbstractText": ["Chinese medicinal herbs (CMH) have been considered a potentially efficacious approach for patients with breast cancer that experience adverse effects from endocrine treatment.", "To investigate the impact of CMH on endocrine therapy-induced side effects in patients with hormone receptor-positive (HR+) breast cancer.", "Ten databases (e.g., PubMed, Web of Science, Cochrane Library, China National Knowledge Information Database and other databases) were searched up to 20 May 2022. The search terms included Chinese herb, breast cancer, endocrine therapy, clinical trial and their mesh terms. The study selection and data extraction were performed by two independent reviewers. The risk of bias was evaluated using the Cochrane risk of bias method.", "A total of 31 studies with 2288 patients were included. There were significant improvements in bone mineral density (BMD) [lumbar BMD (<i>MD</i> 0.08, 95% CI 0.07 to 0.09, <i>p</i>\u2009<\u20090.00001) and femoral neck BMD (<i>MD</i> 0.08, 95% CI 0.07 to 0.10, <i>p</i>\u2009<\u20090.00001)] and bone gal protein (BGP) (<i>MD</i> 0.24, 95% CI 0.17 to 0.31, <i>p</i>\u2009<\u20090.00001), with a significant reduction in triglycerides (MD -0.53, 95% CI -1.00 to -0.07, <i>p</i>\u2009<\u20090.05) and no effect on estradiol levels (MD 0.90, 95% CI -0.31 to 2.12, <i>p</i>\u2009=\u20090.15).", "CMH combined with complementary therapy can moderately reduce endocrine therapy-induced side effects, including bone loss and dyslipidemia in patients with HR\u2009+\u2009breast cancer, revealing the potential role of CMH in treating (HR+) breast cancer. More high-quality RCTs are warranted to further validate the effectiveness and safety of CMH."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China."}], "LastName": "Chen", "ForeName": "Shaoqing", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Health, Fujian Medical University, Fuzhou, China."}], "LastName": "Gao", "ForeName": "Yifang", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China."}], "LastName": "Liu", "ForeName": "Haichao", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China."}], "LastName": "Jing", "ForeName": "Jin", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China."}], "LastName": "Yang", "ForeName": "Zhengyu", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China."}], "LastName": "Zhu", "ForeName": "Haoming", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China."}], "LastName": "Chen", "ForeName": "Bairui", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China."}], "LastName": "Wang", "ForeName": "Yu", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Health, Fujian Medical University, Fuzhou, China."}], "LastName": "Zhang", "ForeName": "Ting", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Health, Fujian Medical University, Fuzhou, China."}, {"Identifier": [], "Affiliation": "Fujian Provincial Collaborative Innovation Center of Geriatric Rehabilitation and Industry Promotion, Fuzhou, China."}], "LastName": "Wang", "ForeName": "Shizhong", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Health, Fujian Medical University, Fuzhou, China."}, {"Identifier": [], "Affiliation": "Fujian Provincial Collaborative Innovation Center of Geriatric Rehabilitation and Industry Promotion, Fuzhou, China."}], "LastName": "Lin", "ForeName": "Jianping", "Initials": "J"}], "PublicationTypeList": ["Meta-Analysis", "Systematic Review", "Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Pharm Biol", "NlmUniqueID": "9812552", "ISSNLinking": "1388-0209"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Breast Neoplasms"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Bone Density"}, {"QualifierName": [], "DescriptorName": "China"}], "CoiStatement": "No potential conflict of interest was reported by the author(s)."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Aggelis V, Johnston SRD.. 2019. Advances in endocrine-based therapies for estrogen receptor-positive metastatic breast cancer. Drugs. 79(17):1849\u20131866.", "ArticleIdList": ["31630379"]}, {"Citation": "Bian WH, Li L, Zhang XQ, Yang J, Ying Y, Le YZ, Chen L, Cao DY.. 2013. Shugan Tiaoyinyang Fang in ameliorating symptoms caused by tamoxifen after breast cancer surgery and improving the quality of life\uff1aaRCT. J Nanjing Univ Trad Chin Med. 29:529\u2013531. Chinese."}, {"Citation": "Boon HS, Olatunde F, Zick SM.. 2007. Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health. 7:4.", "ArticleIdList": ["PMC1851951", "17397542"]}, {"Citation": "Cai JY, Gan JW, Yue SB, Zhuo CL, Chen QT, Zhang GL, Jin Y.. 2021. Effect of Fuzheng Xiaoliu decoction on quality of life, inflammatory factors and sex hormones in postmenopausal breast cancer endocrine therapy patients. Shenzhen J Integr Tradit Chin West Med. 31:71\u201374. Chinese."}, {"Citation": "Cai LL, Guo Q, Cao WL, Wu Y, Guo ZN, Xu Y.. 2018. Effect of Chaiguilongmu decoction in improving adverse reactions of endocrine therapy for breast cancer: a randomized double-blind controlled study. China Pharm. 27:16\u201319. Chinese."}, {"Citation": "Cao Y, Chen Y, Wang P, Lu J, Han X, She J.. 2021. Network pharmacology and experimental validation to explore the molecular mechanisms of Bushen Huoxue for the treatment of premature ovarian insufficiency. Bioengineered. 12(2):10345\u201310362.", "ArticleIdList": ["PMC8810062", "34753385"]}, {"Citation": "Chen Z, Gu K, Zheng Y, Zheng W, Lu W, Shu XO.. 2008. The use of complementary and alternative medicine among Chinese women with breast cancer. J Altern Complement Med. 14(8):1049\u20131055.", "ArticleIdList": ["PMC6461147", "18928393"]}, {"Citation": "Condorelli R, Vaz-Luis I.. 2018. Managing side effects in adjuvant endocrine therapy for breast cancer. Expert Rev Anticancer Ther. 18(11):1101\u20131112.", "ArticleIdList": ["30188738"]}, {"Citation": "Cooke M, Mitchell M, Tiralongo E, Murfield J.. 2012. Complementary and alternative medicine and critical care nurses: a survey of knowledge and practices in Australia. Aust Crit Care. 25(4):213\u2013223.", "ArticleIdList": ["22284371"]}, {"Citation": "Cui Y, Shu XO, Gao YT, Wen WQ, Ruan ZX, Jin F, Zheng W.. 2004. Use of complementary and alternative medicine by Chinese women with breast cancer. Breast Cancer Res Treat. 85(3):263\u2013270.", "ArticleIdList": ["15111765"]}, {"Citation": "Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, et al. . 2013. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 381(9869):805\u2013816.", "ArticleIdList": ["PMC3596060", "23219286"]}, {"Citation": "DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL.. 2019. Breast cancer statistics, 2019. CA Cancer J Clin. 69(6):438\u2013451.", "ArticleIdList": ["31577379"]}, {"Citation": "Ernst E. 2000. Prevalence of use of complementary/alternative medicine: a systematic review. Bull World Health Organ. 78:252\u2013257.", "ArticleIdList": ["PMC2560678", "10743298"]}, {"Citation": "Fu Y, Yun Q, Zhu XM.. 2015. Influences of Heixiaoyao San combined with Shensiwei on clinical measures and quality of life in breast cancer patients with menopausal-like symptoms induced by tamoxifen. Oncol Progr. 13:541\u2013544. Chinese."}, {"Citation": "Gong J. 2019. 42 cases of perimenopausal syndrome after endocrine therapy of breast cancer treated with Guipi decoction. Chiang-hsi Chung I Yao. 50:38\u201340. Chinese."}, {"Citation": "Gong LJ, Lv ZY, Ding XW, Shi J.. 2019. Clinical study on Shugan Liangxue decoction in improving perimenopausal syndrome in the patients with breast cancer using postoperative medical castration. China Mod Doc. 57:127\u2013130. Chinese."}, {"Citation": "Guo L, Wu DL, Du XF.. 2016. Effect of Modified Xiangbei Yangrong Tang based on differentiation in treating metastatic breast cancer treated. Chin J Exp Tradit Med Formulae. 22:160\u2013164. Chinese."}, {"Citation": "Guo Q, Yao C, Guo YF, Wang C.. 2020. Effects of Guilu Sanhuang Decoction combined with calcium on bone metabolism in patients with breast cancer treated by endocrine therapy. Chin J Inf Tradit Chin Med. 27:41\u201345. Chinese."}, {"Citation": "Harris P, Rees R.. 2000. The prevalence of complementary and alternative medicine use among the general population: a systematic review of the literature. Complement Ther Med. 8(2):88\u201396.", "ArticleIdList": ["10859601"]}, {"Citation": "Hu WD. 2018. Clinical Effect of Ruqing Tang combined with western medicine therapy for breast cancer of qi-yin deficiency type. New J Tradit Chin Med. 50:154\u2013156. Chinese."}, {"Citation": "Hu MX, Zhu CX, Xu QQ, Sun KF.. 2020. Effect of Chaishao Jieyu decoction combined with Pingxiao capsule on the patients with luminal breast cancer after operation. J Hainan Med Univ. 26:1640\u20131644. Chinese."}, {"Citation": "Huang XH, Liang RH, Su L, Guo W, Wang CJ.. 2017. Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment. Cancer Biomark. 18(2):183\u2013190.", "ArticleIdList": ["27983533"]}, {"Citation": "Jiang H, Li M, Du K, Ma C, Cheng Y, Wang S, Nie X, Fu C, He Y.. 2021. Traditional Chinese Medicine for adjuvant treatment of breast cancer: Taohong Siwu decoction. Chin Med. 16(1):129.", "ArticleIdList": ["PMC8638166", "34857023"]}, {"Citation": "Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, et al. . 2009. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 27(33):5538\u20135546.", "ArticleIdList": ["19786658"]}, {"Citation": "Kim W, Lee WB, Lee JW, Min BI, Baek SK, Lee HS, Cho SH.. 2015. Traditional herbal medicine as adjunctive therapy for breast cancer: A systematic review. Complement Ther Med. 23(4):626\u2013632.", "ArticleIdList": ["26275657"]}, {"Citation": "Kuo YT, Chang TT, Muo CH, Wu MY, Sun MF, Yeh CC, Yen HR.. 2018. Use of complementary Traditional Chinese Medicines by adult cancer patients in Taiwan: a nationwide population-based study. Integr Cancer Ther. 17(2):531\u2013541.", "ArticleIdList": ["PMC6041896", "28665160"]}, {"Citation": "Lee YK, Lee EG, Kim HY, Lee Y, Lee SM, Suh DC, Yoo JI, Lee S.. 2020. Osteoporotic fractures of the spine, hip, and other locations after adjuvant endocrine therapy with aromatase inhibitors in breast cancer patients: a meta-analysis. J Korean Med Sci. 35(46):e403.", "ArticleIdList": ["PMC7707928", "33258332"]}, {"Citation": "Leggett S, Koczwara B, Miller M.. 2015. The impact of complementary and alternative medicines on cancer symptoms, treatment side effects, quality of life, and survival in women with breast cancer\u2013a systematic review. Nutr Cancer. 67(3):373\u2013391.", "ArticleIdList": ["25811312"]}, {"Citation": "Li CS, Li ZY.. 2021. Clinical observation of Chaihu plus modified Longgu Muli decoction on perimenopausal syndrome of estrogen receptor-positive breast cancer caused by tamoxifen. Hebei J Tradit Chin Med. 43:1620\u20131623. Chinese."}, {"Citation": "Li JJ, Liang LC.. 2017. Clinical observation of aromatase inhibitor-associated osteopenia treated by Bushen therapy. J Shanxi Coll Tradit Chin Med. 18:27\u201329. Chinese."}, {"Citation": "Li S, So TH, Tang G, Tan HY, Wang N, Ng BFL, Chan CKW, Yu EC, Feng Y.. 2020. Chinese herbal medicine for reducing chemotherapy-associated side-effects in breast cancer patients: a systematic review and meta-analysis. Front Oncol. 10:599073.", "ArticleIdList": ["PMC7756083", "33363030"]}, {"Citation": "Li Y, Zhu X, Bensussan A, Li P, Moylan E, Delaney G, McPherson L.. 2016. Herbal medicine for hot flushes induced by endocrine therapy in women with breast cancer: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2016:1327251.", "ArticleIdList": ["PMC4932177", "27418936"]}, {"Citation": "Li XR, Zhu JQ, Tong ZY.. 2019. Effect of Rehmanniae decoction combined with auricular acupuncture on cognitive ability, hormone level, blood lipid and vitamin D content of patients with postmenopausal breast cancer. Chin Arch Tradit Chin Med. 37:246\u2013249. Chinese."}, {"Citation": "Liu H, Zhou L, Zhang QQ, Ling J, Zhang R, Liu LF.. 2021. Influence of strengthening endocrine therapy of Jiawei Erxian decoction joint ovarian function suppression on quality of life, Traditional Chinese Medicine syndromes, blood lipids and sex hormones of breast cancer patient in pre-menopausal hormones with receptor-positive. Hebei J Tradit Chin Med. 43:283\u2013287. Chinese."}, {"Citation": "Molassiotis A, Fern\u00e1ndez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, et al. . 2005. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 16(4):655\u2013663.", "ArticleIdList": ["15699021"]}, {"Citation": "Pei JW, Sun TZ.. 2019. Clinical study of Danzhi Xiaoyao powder combined with Erxian decoction in the treatment of class II climacteric syndrome after endocrine therapy for breast cancer. Acta Chin Med. 34:1973\u20131976. Chinese."}, {"Citation": "Porter D, Cochrane S, Zhu X.. 2017. Current usage of Traditional Chinese Medicine for breast cancer-a narrative approach to the experiences of women with breast cancer in Australia-a pilot study. Medicines (Basel. 4(2):20.", "ArticleIdList": ["PMC5590056", "28930235"]}, {"Citation": "Qiu JS, Wu YY, Liu C.. 2020. Clinical study of Baohe pill in treatment of dyslipidemia in endocrine therapy of breast cancer. Res Integr Tradit Chin West Med. 12:303\u2013307. Chinese."}, {"Citation": "Shi H, Dong J, Xu YB.. 2017. Longniu Bugu decoction for prevention and treatment of bone loss caused by endocrine therapy of premenopausal breast cancer. Chin J Endocr Surg. 11:380\u2013383. Chinese."}, {"Citation": "Shi YF, Wei QL, Zhou LN.. 2014. Yiyuan Shengjing decoction treat similar climacteric syndrome of breast cancer after treated with Tamoxifen. J Zhejiang Chin Med Univ. 38:1172\u20131182. Chinese."}, {"Citation": "Siegel RL, Miller KD, Jemal A.. 2020. Cancer statistics, 2020. CA Cancer J Clin. 70(1):7\u201330.", "ArticleIdList": ["31912902"]}, {"Citation": "Sun Y. 2014. The role of Chinese medicine in clinical oncology. Chin J Integr Med. 20(1):3\u201310.", "ArticleIdList": ["24126976"]}, {"Citation": "Sun XF, Liu H, He YN, Liu CJ, Cui SD.. 2014. Fuzheng Xiaoai decoction 50 cases of syndrome endocrine treatment of breast cancer after operation. Chin J Exp Tradit Med Formulae. 20:192\u2013195. Chinese."}, {"Citation": "Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F.. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3):209\u2013249.", "ArticleIdList": ["33538338"]}, {"Citation": "Tao ZH, Yu XW, Tong X, Fang MH, Jin YJ, Xu ZG, Su Q.. 2020. Clinical observation on the treatment of perimenopausal like syndrome with breast cancer endocrine therapy by Yishen Kang\u2019ai Fang. Smart Healthcare. 6:91\u201394. Chinese."}, {"Citation": "Wang JC, Sun CH, Liu HM, Yan WH.. 2013. Effects of the Tiaohe decoction on premenopausal breast cancer PR(\uff0b) ER(\uff0b) HER-2(\uff0d) endometrium. Clin J Chin Med. 5:15\u201316. Chinese."}, {"Citation": "Wang WS, You JL, Xue Q.. 2017. Efficacy observation of Yishen-chenqian formula treatment Tamoxifen side effects of endocrine stage of breast cancer. Shanxi J Tradit Chin Med. 33:23\u201325. Chinese."}, {"Citation": "Wong CK, Bao YX, Wong EL, Leung PC, Fung KP, Lam CW.. 2005. Immunomodulatory activities of Yunzhi and Danshen in post-treatment breast cancer patients. Am J Chin Med. 33(3):381\u2013395.", "ArticleIdList": ["16047556"]}, {"Citation": "Wu JP, Feng N, Li Y, Bei LM, Li XL, Liu Y, Shi Y, Gao BC, Yang BF.. 2016. Experimental research on the effect of Ruqing decoction on the levels of the hormone for patients with breast cancer of Qi and Yin deficiency syndrome. Inf Tradit Chin Med. 33:53\u201356."}, {"Citation": "Xia YP, Wang H.. 2015. The clinical observation of the treatment of osteoporosis with Jintiange capsules in postmenopausal breast cancer patients after surgery. Chin J Osteoporos. 21:812\u2013816. Chinese."}, {"Citation": "Xiao H, Xi KJ, Fang NQ.. 2019. Modified Zhibai Dihuang decoction alleviating the adverse reactions of letrozole in endocrine therapy for breast cancer. Contemporary Med. 25:9\u201312. Chinese."}, {"Citation": "Yang HF, Luo H, Yang OO, Hu ZJ, He JL, Xu HB.. 2016. Effects of Erzhi pills and Guizhi decoction for the reproductive hormone, modified\u2002Kupperman\u2002score and\u2002ki67\u2002expression of premenopausal\u2002Luminal\u2002type breast cancer patients with tidal fever after treatment. China Med Her. 13:175\u2013178. Chinese."}, {"Citation": "Yin SY, Wei WC, Jian FY, Yang NS.. 2013. Therapeutic applications of herbal medicines for cancer patients. Evid Based Complement Alternat Med. 2013:302426.", "ArticleIdList": ["PMC3727181", "23956768"]}, {"Citation": "Zhang M, Liu X, Li J, He L, Tripathy D.. 2007. Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients. Cochrane Database Syst Rev. 2007(2):CD004921.", "ArticleIdList": ["PMC9028047", "17443560"]}, {"Citation": "Zhang XP, Wang C, Wang QW, Cao SH, Shao XY, Liang S, Feng M, Wang HH, Yao C.. 2020. Study on the effect of Sanhuang decoction on chronic stress and blood viscosity of breast cancer patients. Chin J Surg Oncol. 12:534\u2013538. Chinese."}, {"Citation": "Zhang CL, Zheng YL.. 2012. Clinical study of Dan Zhi Xiao Yao San and Er Zhi Wan Jia Jian in treating the hormone therapy of breast cancer the clinical observation of after menopause syndrome. China J Chin Med. 27:6\u20138. Chinese."}, {"Citation": "Zhong SS, Wan H, Li R, Mao JL, Qu WC, Lu YY, Zhang C.. 2020. Clinical effect of spleen-tonifying and kidney-nourishing prescription in the prevention and treatment of aromatase inhibitor-induced arthralgia. J Anhui Univ Chin Med. 39:20\u201324. Chinese."}, {"Citation": "Zhou J, Zhao F, Zhan XF.. 2020. Clinical observation of similar climacteric syndrome due to breast cancer with endocrine therapy treated by Prosperous Ankun soup. Xinjiang J Tradit Chin Pharm. 38:6\u20139. Chinese."}, {"Citation": "Zhu QL. 2017. Xianlinggubao capsules combined with calcium agents in treatment of osteoporosis due to hormonal therapy after breast cancer operation: effect on bone metabolism. Chin J Gen Surg. 26:670\u2013674. Chinese."}, {"Citation": "Zhu L, Li L, Li Y, Wang J, Wang Q.. 2016. Chinese herbal medicine as an adjunctive therapy for breast cancer: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2016:9469276.", "ArticleIdList": ["PMC4876224", "27239216"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "4", "Day": "26", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "4", "Day": "25", "Hour": "17", "Minute": "42"}, {"Year": "2023", "Month": "4", "Day": "25", "Hour": "8", "Minute": "12"}, {"Year": "2023", "Month": "4", "Day": "25"}], "PublicationStatus": "ppublish", "ArticleIdList": ["37096936", "PMC10132232", "10.1080/13880209.2023.2203193"]}}], "PubmedBookArticle": []}